Αρχική World News Nivolumab vs Sorafenib in First-Line Treatment of Advanced Hepatocellular Carcinoma

Nivolumab vs Sorafenib in First-Line Treatment of Advanced Hepatocellular Carcinoma

At a minimum follow-up of 33.6 months, nivolumab as a first-line treatment for advanced hepatocellular carcinoma did not show statistically longer overall survival (OS) over monotherapy with sorafenib. Nivolumab had a more favourable and manageable safety profile and greater preservation of liver function over time compared with sorafenib, according to Dr Bruno Sangro of the Clinica Universidad de Navarra and CIBEREHD in Pamplona, Spain and colleagues who presented the long-term findings from the CheckMate 459 study at ESMO World Congress on Gastrointestinal Cancer 2020 Virtual (1-4 July).

The study team wrote in the background that patients with advanced hepatocellular carcinoma who are not amenable to surgical resection or locoregional therapy may be treated with multitargeted kinase inhibitors or immune checkpoint inhibitor-based combination therapy.

Sorafenib is approved as first-line treatment in that setting. However, it provides only a modest survival benefit. Despite currently approved first-line treatments for advanced hepatocellular carcinoma, prolonging survival while improving treatment tolerability remains an unmet medical need.

The CheckMate 459 study (NCT02576509) is a phase III trial that compared first-line treatment with nivolumab vs sorafenib in patients with advanced hepatocellular carcinoma. Initial efficacy and safety data were previously presented by Yau et al. at ESMO 2019 Congress in Barcelona who reported that the protocol-defined statistical significance threshold for OS was not met, although nivolumab showed clinical benefit.

At ESMO World Congress on Gastrointestinal Cancer 2020 Virtual, the study team presented long-term follow-up results. In CheckMate 459, 743 systemic therapy-naive patients at least 18 years old with advanced hepatocellular carcinoma and Child-Pugh A liver function were randomised 1:1 to nivolumab (n = 371) or sorafenib (n = 372). The study primary endpoint was OS. Secondary endpoints were objective response rate and progression-free survival by blinded independent central review per RECIST v1.1, efficacy by PD-L1 tumour cell expression, and safety.

The authors reported that with a minimum follow-up of 33.6 months, nivolumab demonstrated longer median OS of 16.4 months (95% confidence interval [CI] 14.0-18.5) vs 14.8 months with sorafenib (95% CI 12.1-17.3), hazard ratio (HR) 0.85 (95% CI 0.72-1.00); nominal p value = 0.0522. The 33-month OS rates for nivolumab and sorafenib were 29% (95% CI 25-34) and 21% (95% CI 17-25), respectively.

Futhermore, the authors reported that a consistent benefit was observed with nivolumab regardless of baseline PD-L1 expression (PD-L1 ≥1% HR 0.80, 95% CI 0.54-1.17; PD-L1 <1% HR 0.84, 95% CI 0.70-1.01). Median OS in patients with PD-L1 ≥1% was longer with nivolumab vs sorafenib, 16.1 months (95% CI 8.4-22.3) vs 8.6 months (95% CI 5.7-16.3), respectively.

Among patients with hepatitis C virus (HCV) and hepatitis B virus (HBV) aetiology, median OS was numerically longer with nivolumab versus sorafenib, 17.5 vs 12.7 months (HR 0.72, 95% CI 0.51-1.02) for HCV and 16.1 vs 10.4 months (HR 0.79, 95% CI 0.59-1.07) for HBV, respectively.

Nivolumab demonstrated greater liver function preservation over time than sorafenib as evidenced by albumin-bilirubin levels and Child-Pugh scores.

Seven patients (2%) in the nivolumab arm and 77 patients (21%) in the sorafenib arm received subsequent therapy with immune checkpoint inhibitor.

Nivolumab demonstrated a more favourable safety profile compared with sorafenib, with grade 3-4 treatment-related adverse events occurring in 82 patients (22.3%) and 180 patients (49.6%), respectively.

The authors concluded that a long-term follow-up data of CheckMate 459 study show for 1,5 months longer OS with first-line nivolumab than with sorafenib in the management of advanced hepatocellular carcinoma, but this difference was not statistically significant. Nivolumab had a more favourable and manageable safety profile and greater preservation of liver function over time compared with sorafenib, which is consistent with previous reports. There were no new or unexpected safety signals observed.

The study was funded by Bristol Myers Squibb (Princeton, NJ, USA).


LBA3 – Sangro B, Park J, Finn R, et al. CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma. ESMO World Congress on Gastrointestinal Cancer 2020 Virtual (1-4 July).



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Making Important Decisions During Cancer: A Survivor’s Story

Bethany Hart lives with her husband Kevin, sons, and 3 dogs in the suburbs of Indianapolis, Indiana. She is a survivor of small cell neuroendocrine cervical cancer....

Adjuvant Immunotherapy Approved for Some Patients with Lung Cancer

October 26, 2021, by NCI Staff Atezolizumab (Tecentriq) is approved as an additional treatment for some patients with stage II to IIIA (pictured) non-small cell...

Cure Probability Models for Evaluation of Patients with a Previous Cancer Diagnosis for Solid Organ Transplantation

Findings from a first study that applied a formal statistical framework to inform the evaluation of transplant candidates with a previous cancer diagnosis were...

Teacher Reads To Students One Day After Having Brain Surgery

Meucci - who had her surgery on a Wednesday - was going live from her intensive care unit hospital room that very next Thursday...

6 things you need to know about cervical screening

This article was originally published in 2017 during Cervical Screening Awareness Week. It has now been reviewed and updated. Cervical screening, also known as the...

EMA Recommends Granting a Marketing Authorisation for Sacituzumab Govitecan

On 14 October 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...